| AMPLYFICompanies | Cardiff company that ran an AI market-intelligence platform; in voluntary liquidation since April 2026. wound_down | Cardiff | Companies House · businessnewswales.com/innovation-investment-capi · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. | one source |
| AntiverseCompanies | Cardiff company that uses AI to design antibody drugs against targets that are hard to reach with existing methods.Profile- Founders
- Murat Tunaboylu — co-founder and CEO; Ben Holland — co-founder and CTO
- Chief executive
- Murat Tunaboylu
- Chief scientist or research lead
- Ben Holland — CTO; Gherici Hassaine — Director of Antibody Discovery
- Other leaders
- Michelle Mighdoll — VP Corporate and Business Development; Huw Whyment — Head of Operations; Thane Kreiner — Board Chair; Charles Kunsch — non-executive director
- Hq
- Cardiff (Wales); other_offices: Boston, USA; Prague, Czechia (Outside the UK)
- What it does
- Antiverse designs antibodies with in-house AI and tests them in its own lab, focusing on hard drug targets such as GPCRs (cell-surface receptors). Its "lab in a loop" feeds lab results back into the AI models. It works with pharma companies and foundations.
- Research focus
- "We pair in-house AI with … lab science to design the next generation of GPCR therapeutics."
- Models and products
- Antiverse Platform — AI antibody and nanobody design (design, function, developability, learn layers) with native-membrane screening — not stated; AntiConf — confidence metric for predicted antibody–antigen complexes — 28 Mar 2026; UDIZ-007 — anti-PD-1 antibody (preprint) — 15 Jul 2026
- Customers or partners named
- Cystic Fibrosis Foundation — antibodies against CFTR — 10 Mar 2026 — https://www.antiverse.io/news; Nxera Pharma — GPCR antibody collaboration using generative AI — on or before 28 Dec 2024 — https://www.antiverse.io/news; GlobalBio, Inc. — extended antibody cancer therapeutics collaboration — 16 Oct 2023 — https://www.antiverse.io/news
- Selected papers
- Advances in Therapeutic Antibody Discovery and Development Targeting G Protein-Coupled Receptors — venue not stated — 20 Jan 2026 — https://www.antiverse.io/platform; Confidence scoring for deep learning-predicted antibody–antigen complexes: AntiConf as a precision-driven metric — venue not stated — 28 Mar 2026 — https://www.antiverse.io/platform; Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1 — venue not stated — 25 Nov 2025 — https://www.antiverse.io/platform; Non-Clinical Evaluation of the Anti-PD-1 Antibody UDIZ-007 — preprint — 15 Jul 2026 — https://www.antiverse.io/platform
- Funding total as published
- more than $20m — as of 3 Mar 2026 — https://tech.eu/2026/03/03/antiverse-secures-93m-series-a-for-ai-antibody-platform/
- Rounds found
- 18 Mar 2021 — seed — £1.4m — angel syndicate led by Ed Parkinson (already DEAL-LAB-4022); 3 Mar 2026 — Series A — $9.3m — Soulmates Ventures — Innovation Investment Capital, DOMiNO Ventures; existing DBW, Kadmos Capital, i&i Biotech Fund (already DEAL-INV-015 / DEAL-SU-HLT-012)
- Status now
- Trading; closed a $9.3m Series A in March 2026 and began a research agreement with the Cystic Fibrosis Foundation.
Labs Round 8 deep profile (31 Oct 2026), as the researchers wrote it; confidence: verified (Series A: company news page plus trade); total raised one source. Sources - antiverse.io/about
- antiverse.io/news
- tech.eu/2026/03/03/antiverse-secures-93m-series-
Models and products (2)- AntiConf (antibody-antigen confidence score) 2026-03-28 released (paper)Antiverse method that scores how far to trust AI-predicted structures of antibodies bound to their targets.
- Antiverse Platform — (date not stated) live (in-house and partnered discovery)Antiverse's AI system for designing antibodies against hard drug targets such as GPCRs and ion channels.
| Cardiff (CF24 4HQ) | Companies House · uktech.news/ai/welsh-biotech-raises-7m-for-ai-de · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. · uktech.news/featured/wales-antibody-drug-discove | verified |
| CanSenseCompanies | Blood test for bowel cancer that reads samples with laser light and artificial intelligence. | Swansea (SA2 8PP ) | Companies House · uktech.news/medtech/cansense-funding-20230309 · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. | verified |
| iTero GamingCompanies | Made AI coaching software for competitive gamers that analysed past matches and suggested characters and tactics; bought by esports group GIANTX in 2024. acquired | Cardigan, West Wales | Companies House · uktech.news/tech-hubs/wales/esports-itero-gaming · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. | verified |
| Nisien.AICompanies | Cardiff University spin-out whose software uses AI to detect and classify online harms in real time. | Cardiff (CF24 4HQ) | Companies House · foresight.group/news-insights/news/2025/welsh-ai · businesscloud.co.uk/news/cardiff-ai-startup-secu · british-business-bank.co.uk/nations-and-regions- · find-and-update.company-information.service.gov. | verified |
| Optimise-AICompanies | Cardiff firm building generative-AI software to cut energy use in non-domestic buildings without a building management system. active (DESNZ grant) | Cardiff | gov.uk/government/publications/artificial-intell · gov.uk/government/news/government-backing-for-ai | verified |